AR and neoplasm: A recent study also demonstrated that NSD2 plays a pivotal role in prostate tumorigenesis, where NSD2-mediated H3K36me2 is required for androgen receptor (AR) transactivation through de novo formation of tumor-specific AR enhancers in AR-dependent prostate cancer [114].